Persantin Retard 200mg capsules

Country: United Kingdom

Bahasa: Inggeris

Sumber: MHRA (Medicines & Healthcare Products Regulatory Agency)

Bahan aktif:

Dipyridamole

Boleh didapati daripada:

Boehringer Ingelheim Ltd

Kod ATC:

B01AC07

INN (Nama Antarabangsa):

Dipyridamole

Dos:

200mg

Borang farmaseutikal:

Modified-release capsule

Laluan pentadbiran:

Oral

Kelas:

No Controlled Drug Status

Jenis preskripsi:

Valid as a prescribable product

Ringkasan produk:

BNF: 02090000; GTIN: 5012816070271

Risalah maklumat

PACKAGE LEAFLET:
INFORMATION FOR THE USER:
PERSANTIN
® RETARD 200MG
CAPSULES
(dipyridamole)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU
START TAKING THIS MEDICINE.
Keep this leaflet. You may need to read it
again.
If you have any further questions, ask
your doctor or pharmacist.
This medicine has been prescribed for
you. Do not pass it on to others. It may
harm them, even if their symptoms are the
same as yours.
If any of the side effects gets troublesome
or serious, or if you notice any side effects
not listed in this leaflet, please tell your
doctor or pharmacist.
The name of your medicine is Persantin
Retard 200mg Capsules, but it will be referred
as Persantin Retard throughout this leaflet.
IN THIS LEAFLET:
1.
What Persantin Retard is and what it is
used for
2.
Before you take Persantin Retard
3.
How to take Persantin Retard
4.
Possible side effects
5.
How to store Persantin Retard
6.
Further information
1.
WHAT PERSANTIN RETARD IS AND
WHAT IT IS USED FOR
The name of your medicine is Persantin
Retard. It contains a medicine called
Dipyridamole. This belongs to a group of
medicines called ‘anti-thrombotic agents’,
which are used to help stop blood clots
forming.
Persantin Retard is used:
To help stop blood clots which may occur
if you have had your heart valves
replaced.
In people who have had a stroke caused
by a blood clot in the brain. This medicine
reduces the risk of having another stroke.
2.
BEFORE YOU TAKE PERSANTIN
RETARD
DO NOT TAKE PERSANTIN RETARD IF YOU ARE
ALLERGIC (HYPERSENSITIVE) TO:
Dipyridamole
Any of the other ingredients of Persantin
Retard (see section 6: ‘Further
Information’)
TAKE SPECIAL CARE WITH PERSANTIN RETARD
Check with your doctor or pharmacist before
taking your medicine if:
You have angina or other heart problems
(including heart valve or circulation
problems) or have had a recent heart
attack
You have myasthenia gravis (a rare
muscle problem)
You have any bleeding problems
You are pregnant or planning to become
pregnant or are breast-feeding
If you are not sure if any

Ciri produk

OBJECT 1
PERSANTIN RETARD 200 MG
Summary of Product Characteristics Updated 02-Mar-2015 | Boehringer
Ingelheim Limited
1. Name of the medicinal product
Persantin
®
Retard 200 mg Modified Release Capsules, Hard
2. Qualitative and quantitative composition
Each modified release capsule contains dipyridamole 200 mg.
For excipients, see 6.1
3. Pharmaceutical form
Modified release capsules, hard.
Hard gelatin capsules consisting of a red cap and an orange body.
4. Clinical particulars
4.1 Therapeutic indications
- Secondary prevention of ischaemic stroke and transient ischaemic
attacks either alone or in conjunction
with aspirin.
- An adjunct to oral anti-coagulation for prophylaxis of
thromboembolism associated with prosthetic heart
valves.
4.2 Posology and method of administration
For oral administration.
Adults, including the elderly
The recommended dose is one capsule twice daily, usually one in the
morning and one in the evening
preferably with meals.
The capsules should be swallowed whole without chewing.
Children
PERSANTIN Retard 200 mg is not recommended for children.
4.3 Contraindications
Hypersensitivity to any component of the product.
4.4 Special warnings and precautions for use
Among other properties, dipyridamole acts as a potent vasodilator. It
should therefore be used with
caution in patients with severe coronary artery disease including
unstable angina and/or recent myocardial
infarction, left ventricular outflow obstruction or haemodynamic
instability (e.g. decompensated heart
failure).
Patients being treated with regular oral doses of PERSANTIN Retard
should not receive additional
intravenous dipyridamole. Clinical experience suggests that patients
being treated with oral dipyridamole
who also require pharmacological stress testing with intravenous
dipyridamole, should discontinue drugs
containing oral dipyridamole for twenty-four hours prior to stress
testing.
In patients with myasthenia gravis readjustment of therapy may be
necessary after changes in
dipyridamole dosage. (See Interactions).
PERSAN